The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Exelixis today and set a price target of $35.00. According to TipRanks, Archila is a 5-star analyst with an average return of 19.4% and a ...

Exelixis is undervalued, trading at a discount to sector and historical multiples despite robust double-digit growth and operational excellence. EXEL maintains high margins, generates strong FCF, and ...

Looking ahead to 2030, our model projects EXEL could trade at an average price of $72.09, with a potential range between $54.07 and $90.11. This represents a potential 61.5% return from today's price.

Short interest in Exelixis Inc (NASDAQ:EXEL) increased during the last reporting period, rising from 27.26M to 28.31M. This put 15.1% of the company's publicly available shares short. Based on the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...

Exelixis Inc. Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Exelixis (EXEL), which belongs to the Zacks ...